FOSCHI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.197
EU - Europa 742
AS - Asia 160
AF - Africa 1
Totale 2.100
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.194
SE - Svezia 158
PL - Polonia 136
IE - Irlanda 133
UA - Ucraina 108
HK - Hong Kong 97
IT - Italia 65
DE - Germania 60
FI - Finlandia 37
CN - Cina 34
GB - Regno Unito 20
CH - Svizzera 15
TR - Turchia 12
FR - Francia 8
JO - Giordania 8
IN - India 4
CA - Canada 3
BE - Belgio 2
KR - Corea 2
VN - Vietnam 2
MU - Mauritius 1
SG - Singapore 1
Totale 2.100
Salva come PNG Salva come JPEG
Città #
Jacksonville 156
Fairfield 140
Warsaw 136
Chandler 135
Dublin 133
Cambridge 75
Woodbridge 75
Ashburn 68
Seattle 65
Hong Kong 64
Houston 50
Wilmington 46
Princeton 37
Ann Arbor 33
Buffalo 32
Boardman 31
Boston 29
Beijing 19
Bern 14
Medford 13
Altamura 10
Norwalk 10
Lawrence 9
Izmir 8
New York 8
San Diego 8
Shanghai 8
Dearborn 7
Milan 7
Frankfurt Am Main 5
Auburn Hills 3
Bremen 3
Falls Church 3
Hillsboro 3
Pune 3
Verona 3
Andover 2
Bra 2
Brussels 2
Dong Ket 2
Florence 2
Hanover 2
Kunming 2
Los Angeles 2
Nanjing 2
Salerno 2
Toronto 2
West Jordan 2
Ashford 1
Bagno a Ripoli 1
Bari 1
Brescia 1
Guangzhou 1
Old Bridge 1
Ottawa 1
Phoenix 1
Redmond 1
San Mateo 1
San Severino Marche 1
Valverde 1
Washington 1
Wollerau 1
Zhengzhou 1
Totale 1.488
Salva come PNG Salva come JPEG
Nome #
Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis 238
Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide. 101
Torasemide in the treatment of patients with cirrhosis and ascites. 91
Infection of peripheral mononuclear blood cells by hepatitis C virus 81
Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites. 81
Blunted natriuretic response to low-dose brain natriuretic peptide infusion in nonazotemic cirrhotic patients with ascites and avid sodium retention. 81
Pathogenesis and treatment of ascites in hepatic cirrhosis. 77
Loop diuretic therapy in liver cirrhosis with ascites 76
Respiratory mechanics in patients with tense cirrhotic ascites. 74
Changes in the production of nitric oxide and superoxide by inflammatory cells in liver cirrhosis. 71
Acetaldehyde inhibits PPARgamma via H2O2-mediated c-Abl activation in human hepatic stellate cells. 69
Vascular reserve in the lower limbs of cirrhotic patients: a duplex Doppler ultrasound study. 68
Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis 65
Increased production of nitric oxide by neutrophils and monocytes from cirrhotic patients with ascites and hyperdynamic circulation. 62
Gestione avanzata dell’ictus ischemico acuto. Due anni di attività dello Stroke Team dell’Ospedale di Careggi, Firenze. 61
Renal impairement in chronic liver diseases with and without cholestasis 58
Continuous recording of dicrotic and pulse pressures during head-up tilting test: the vasodepressive profile. Preliminary data. 50
Acetaldehyde inhibits peroxisome proliferator-activated receptor gamma (PPARg) transcriptional activity in hepatic stellate cells. A MAPk/pkcdelta-dependent mechanism. 49
Cerebral autoregulation in patients with cirrhosis and ascites. A transcranial Doppler study. 47
Le epatiti croniche 46
Baroreflex function in vasodepressive syncope: detection of early impairment.Med Sci Monit. 2003 Mar;9(3):CR125-30. 43
EFFECTS OF RECOMBINANT HUMAN GAMMA-INTERFERON ON ADVANCED HEPATOCELLULAR CARCINOMA 41
Treatment of chronic HCV hepatitis by reconbimant human interferon alpha: preliminary report of an in progress study 39
Effects of recombinant human gamma-interferon on advanced hepatocellular carcinoma 39
Different effects of atrial and C-type natriuretic peptide on the renal release of endothelin-1 in man 38
Therapy of chronic active hepatitis C with alfa interferon: effectiveness and prognostic factors 38
Refractory ascites: definition, pathogenesis and treatment. 35
TREATMENT OF CHRONIC HCV HEPATITIS BY RECOMBINANT HUMAN INTERFERON ALPHA:PRELIMINARY REPORT OF AN IN PROGRESS STUDY 34
Epatite da virus C e terapia interferonica 34
THERAPY OF CHRONIC ACTIVE HEPATITIS C WITH ALFA INTERFERON:EFFECTINEVESS AND PROGNOSTIC FACTORS 33
L'Impiego dell'INterferone Alfa Ricombinante nel Trattamento della Cirrosi Attiva anti-HCV positiva. 33
Il Fegato: Fisiopatologia, Clinica, Terapia 31
Terapia interferonica dell'epatite cronica attiva HCV-correlata con e senza cirrosi 30
Renal Impairment In Chronic Liver-Diseases With And Without Cholestasis. 30
Recenti dati sulle epatiti virali acute e croniche 25
Role of HCV and HBV infection in alcoholic liver disease: HCV RT (reverse transcriptase) PCR (polymerase chain reaction ) and HBV PCR analysis 20
Therapy Of Chronic Active Hepatitis-C With Alpha-Interferon - Effectiveness And Prognostic Factors 17
Totale 2.106
Salva come PNG Salva come JPEG
Categoria #
all - tutte 5.749
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.749
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019114 0 0 0 0 0 0 0 0 0 0 63 51
2019/2020419 29 40 11 42 34 55 48 58 32 18 44 8
2020/2021303 25 11 33 30 7 54 3 31 20 43 19 27
2021/2022216 3 26 8 10 5 6 5 10 10 5 67 61
2022/2023552 53 46 33 38 52 121 74 31 61 5 21 17
2023/2024220 11 25 38 10 14 23 3 78 11 7 0 0
Totale 2.106